Local and global limits on visual processing in schizophrenia.

PLoS One

Department of Optometry & Vision Science, University of Auckland, Private Bag, Auckland, New Zealand.

Published: January 2016

Schizophrenia has been linked to impaired performance on a range of visual processing tasks (e.g. detection of coherent motion and contour detection). It has been proposed that this is due to a general inability to integrate visual information at a global level. To test this theory, we assessed the performance of people with schizophrenia on a battery of tasks designed to probe voluntary averaging in different visual domains. Twenty-three outpatients with schizophrenia (mean age: 40±8 years; 3 female) and 20 age-matched control participants (mean age 39±9 years; 3 female) performed a motion coherence task and three equivalent noise (averaging) tasks, the latter allowing independent quantification of local and global limits on visual processing of motion, orientation and size. All performance measures were indistinguishable between the two groups (ps>0.05, one-way ANCOVAs), with one exception: participants with schizophrenia pooled fewer estimates of local orientation than controls when estimating average orientation (p = 0.01, one-way ANCOVA). These data do not support the notion of a generalised visual integration deficit in schizophrenia. Instead, they suggest that distinct visual dimensions are differentially affected in schizophrenia, with a specific impairment in the integration of visual orientation information.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331538PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0117951PLOS

Publication Analysis

Top Keywords

visual processing
12
local global
8
global limits
8
visual
8
limits visual
8
years female
8
schizophrenia
7
processing schizophrenia
4
schizophrenia schizophrenia
4
schizophrenia linked
4

Similar Publications

Background: The regulatory role of the apolipoprotein E (APOE) ε4 allele in the clinical manifestations of spinocerebellar ataxia type 3 (SCA3) remains unclear. This study aimed to evaluate the impact of the APOE ε4 allele on cognitive and motor functions in SCA3 patients.

Methods: This study included 281 unrelated SCA3 patients and 182 controls.

View Article and Find Full Text PDF

Purpose: This study compares the functional outcomes of correction using two different types of aberrational extended depth-of-focus (EDOF) intraocular lenses (IOLs).

Material And Methods: The study was conducted in two standardized groups (20 patients, 20 eyes in each group). Patients in group 1 were implanted EDOF IOL I, in group 2 - EDOF IOL II.

View Article and Find Full Text PDF

Preparation for cataract surgery in patients with keratoconus (KC) is associated with particular challenges: calculating the optical power of the intraocular lens (IOL), selecting the appropriate IOL model, and considering additional interventions aimed at stabilizing KC and reducing irregular astigmatism. This article presents a fundamentally new approach to combined treatment of KC with cataract, consisting of two stages: first, performing bandage therapeutic-optical keratoplasty (BTOK), followed by cataract phacoemulsification as the second stage.

View Article and Find Full Text PDF

The introduction of faricimab, a drug targeting both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2, has enabled the implementation of the highly effective dual inhibition strategy in real clinical practice for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), both previously treated with intravitreal injections and newly diagnosed. This article presents a series of 11 clinical cases involving patients with nAMD and DME who received loading doses of faricimab and continued ophthalmological observation. Among them, three patients with nAMD and two with DME were treatment-naïve, while the others were switched from alternative therapies to faricimab.

View Article and Find Full Text PDF

Unlabelled: Diabetic macular edema (DME) is a leading cause of visual impairment and blindness among diabetic patients, its prevalence is continuing to increase worldwide. Faricimab, a bispecific antibody, represents a new generation of treatments for DME.

Purpose: This study presents an indirect comparison of the effectiveness and safety of faricimab versus other treatment options for DME.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!